A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery

Transfusion

Volumn 48, Issue SUPPL. 1, 2008, Pages

  Despotis, George ^a   Eby, Charles ^a   Lublin, Douglas M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTITHROMBIN III; ARGATROBAN; CLOPIDOGREL; DANAPAROID; DERMATAN; DESMOPRESSIN; EPTIFIBATIDE; HEMOGLOBIN; HEPARIN; HEPARIN COFACTOR II; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NITROUS OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMIN; PROTAMINE; PROTEIN C; PROTEIN S; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR XIIIA; TIROFIBAN; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; UROKINASE; VITAMIN K GROUP; WARFARIN;

ACUTE KIDNEY FAILURE; ARTERY THROMBOSIS; BLEEDING; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DEATH; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG FATALITY; ERYTHROCYTE TRANSFUSION; HEART INFARCTION; HEART SURGERY; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; INCIDENCE; LUNG EMBOLISM; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; RISK ASSESSMENT; SIDE EFFECT; STROKE; SURVIVAL; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME;

BLOOD PLATELETS; BLOOD TRANSFUSION; ERYTHROCYTES; HEMORRHAGE; HEMOSTASIS; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; IMMUNE SYSTEM DISEASES; MULTIPLE ORGAN FAILURE; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RISK; THORACIC SURGERY;

EID: 43149097379     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01573.x     Document Type: Conference Paper

References (302)

1. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine: blood transfusion. N Engl J Med 1999 340 : 438 47.
2. Walker RH. Special report: transfusion risks. Am J Clin Pathol 1987 88 : 374 8.
3. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003 361 : 161 9.
4. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA TRALI Consensus Panel. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005 1919 : 2 31.
5. McCullough J. Complications of transfusion. In : McCullough J, editor. Transfusion medicine. 1st ed. New York (NY) : McGraw-Hill 1999. p. 337 59.
6. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004, 1774 89.
7. Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, Dodd RY, Benjamin RJ. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007 47 : 599 607.
8. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990 30 : 583 90.
9. Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, Wagner S, Dodd RY, Benjamin R J, and the America Red Cross Regional Blood Centers. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007 47 : 1134 42.
10. Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion 1992 32 : 601 6.
11. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002 42 : 975 9.
12. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
13. Kleinman S, Glynn SA, Busch M, Todd D, Powell L, Pietrelli L, Nemo G, Schreiber G, Bianco C, Katz L. The 2003 West Nile virus United States epidemic: the America's Blood Centers experience. Transfusion 2005 45 : 469 79.
14. Noninfectious complications of blood transfusion. In : Brecher ME, editor. AABB technical manual. 14th ed. Bethesda (MD) : American Association of Blood Banks 2002. p. 586 7.
15. Edna TH, Bjerkeset T. Association between blood transfusion and infection in injured patients. J Trauma 1992 33 : 659 61.
16. Agarwal N, Murphy JG, Cayten CG, Stahl WM. Blood transfusion increases the risk of infection after trauma. Arch Surg 1993 128 : 171 6.
17. Triulzi DJ, Vanek K, Ryan DH, Blumberg N. A clinical and immunologic study of blood transfusion and postoperative bacterial infection in spinal surgery. Transfusion 1992 32 : 517 24.
18. Jensen LS, Andersen AJ, Christiansen PM, Hokland P, Johl CO, Madsen G, Mortensen J, Moller-Nielsen C, Hanberg-Sorensen F, Hokland M. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992 79 : 513 6.
19. Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996 348 : 841 5.
20. Edna TH, Bjerkeset T. Association between transfusion of stored blood and infective bacterial complications after resection for colorectal cancer. Eur J Surg 1998 164 : 449 56.
21. Tartter PI. The association of perioperative blood transfusion with colorectal cancer recurrence. Ann Surg 1992 216 : 633 8.
22. Tartter PI. Blood transfusion and infectious complications following colorectal cancer surgery. Br J Surg 1988 75 : 789 92.
23. Vignali A, Braga M, Dionigi P, Radaelli G, Gentilini O, Bellini A, Jemos V, Di Carlo V. Impact of a programme of autologous blood donation on the incidence of infection in patients with colorectal cancer. Eur J Surg 1995 161 : 487 92.
24. Houbiers JG, van de Velde CJ, van de Watering LM, Hermans J, Schreuder S, Bijnen AB. Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: a prospective study. Transfusion 1997 37 : 126 34.
25. Murphy PJ, Connery C, Hicks GL Jr, Blumberg N. Homologous blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1992 104 : 1092 9.
26. Chelemer SB, Prato BS, Cox PM Jr, O'Connor GT, Morton JR. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg 2002 73 : 138 42.
27. Tartter PI, Mohandas K, Azar P, Endres J, Kaplan J, Spivack M. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998 176 : 462 6.
28. Baron JF, Gourdin M, Bertrand M, Mercadier A, Delort J, Kieffer E, Coriat P. The effect of universal leukodepletion of packed red blood cells on postoperative infections in high-risk patients undergoing abdominal aortic surgery. Anesth Analg 2002 94 : 529 37.
29. Titlestad IL, Ebbesen LS, Ainsworth AP, Lillevang ST, Qvist N, Georgsen J. Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications. Results of a double-blinded, randomized study. Int J Colorectal Dis 2001 16 : 147 53.
30. Wallis JP, Chapman CE, Orr KE, Clark SC, Forty JR. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion 2002 42 : 1127 34.
31. Sauaia A, Moore FA, Moore EE, Haenel JB, Read RA, Lezotte DC. Early predictors of postinjury multiple organ failure. Arch Surg 1994 129 : 39 45.
32. Sauaia A, Moore FA, Moore EE, Norris JM, Lezotte DC, Hamman RF. Multiple organ failure can be predicted as early as 12 hours after injury. J Trauma 1998 45 : 291 301.
33. Moore FA, Moore EE, Sauaia A. Blood transfusion. An independent risk factor for postinjury multiple organ failure. Arch Surg 1997 132 : 620 4.
34. Chin-Yee I, Keeney M, Krueger L, Dietz G, Moses G. Supernatant from stored red cells activates neutrophils. Transfusion Medicine 1998 8 : 49 56.
35. van Bommel J, de Korte D, Lind A, Siegemund M, Trouwborst A, Verhoeven AJ, Ince C, Henny CP. The effect of transfusion of stored RBCs on intestinal microvascular oxygenation in the rat. Transfusion 2001 41 : 1515 23.
36. Tinmoth A, Chin-Yee I. The clinical consequences of the red cell storage lesion. Transfusion Medicine Reviews 2001 15 : 91 107.
37. Wallis JP. Nitric oxide and blood: a review. Transfusion Medicine 2005 15 : 1 11.
38. van de Watering LM, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F, Harvey MS, Huysmans HA, Brand A. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998 97 : 562 8.
39. Hebert PC, Wells G, Tweeddale M, Martin CM, Marshall J, Pham B, Blajchman M, Schweitzer I, Pagliarello G. Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med 1997 155 : 1618 23.
40. Bracey AW, Radovancevic R, Riggs SA, Houston S, Cozart H, Vaughn WK, Radovancevic B, McAllister HA Jr, Cooley DA. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion 1999 39 : 1070 7.
41. Bilgin YM, van de Watering LM, Eijsman L, Versteegh MI, Brand R, van Oers MH, Brand A. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004 109 : 2755 60.
42. Habib RH, Zacharias A, Schwann TA, Riordan CJ, Engoren M, Durham SJ, Shah A. Role of hemodilutional anemia and transfusion during cardiopulmonary bypass in renal injury after coronary revascularization: implications on operative outcome. Crit Care Med 2005 33 : 1749 56.
43. Fung MK, Rao N, Rice J, Ridenour M, Mook W, Triulzi DJ. Leukoreduction in the setting of open heart surgery: a prospective cohort-controlled study. Transfusion 2004 44 : 30 5.
44. Basran S, Frumento RJ, Cohen A, Lee S, Du Y, Nishanian E, Kaplan HS, Stafford-Smith M, Bennett-Guerrero E. The association between duration of storage of transfused red blood cells and morbidity and mortality after reoperative cardiac surgery. Anesth Analg 2006 103 : 15 20.
45. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, Murkin J, Nadel A. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004 44 : 1143 8.
46. Bucerius J, Gummert JF, Borger MA, Walther T, Doll N, Onnasch JF, Metz S, Falk V, Mohr FW. Stroke after cardiac surgery: a risk factor analysis of 16,184 consecutive adult patients. Ann Thorac Surg 2003 75 : 472 8.
47. Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002 74 : 1180 6.
48. Karkouti K, Wijeysundera DN, Yau TM, Callum JL, Meineri M, Wasowicz M, McCluskey SA, Beattie WS. Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery. Can J Anaesth 2006 53 : 279 87.
49. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996 111 : 1037 46.
50. Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, Quinn RD, Nugent WC, Birkmeyer JD, O 'Connor GT. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998 133 : 442 7.
51. Unsworth-White MJ, Herriot A, Valencia O, Poloniecki J, Smith EE, Murday AJ, Parker DJ, Treasure T. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 1995 59 : 664 7.
52. Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, Ghannam M, Yeo E, Djaiani G, Karski J. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004 44 : 1453 62.
53. Frumento RJ, O'Malley CM, Bennett-Guerrero E. Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg 2003 75 : 479 83.
54. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002 347 : 1309 17.
55. Koch CG, Li L, Duncan AI, Mihaljevic T, Loop FD, Starr NJ, Blackstone EH. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg 2006 81 : 1650 7.
56. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004 104 : 1243 52.
57. Gomez-Moreno G, Cutando-Soriano A, Arana C, Scully C. Hereditary blood coagulation disorders: management and dental treatment. J Dent Res 2005 84 : 978 85.
58. Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia 2002 8 : 308 21.
59. Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996 82 : 13 21.
60. Kirkpatrick AW, Chun R, Brown R, Simons RK. Hypothermia and the trauma patient. Can J Surg 1999 42 : 333 43.
61. Heimark RL, Kurachi K, Fujikawa K, Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980 286 : 456 60.
62. Boisclair MD, Lane DA, Philippou H, Esnouf P, Sheikh S, Hunt B, Smith KJ. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993 82 : 3350 7.
63. de Haan J, Boonstra PW, Monnink SH, Ebels T, van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann Thorac Surg 1995 59 : 901 7.
64. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2. Thromb Haemost 1993 70 : 253 8.
65. Menges T, Wagner RM, Welters I, Ruwoldt R, Boldt J, Hempelmann G. The role of the protein C-thrombomodulin system and fibrinolysis during cardiovascular surgery: influence of acute preoperative plasmapheresis. J Cardiothorac Vasc Anesth 1996 10 : 482 9.
66. Hunt BJ, Parratt RN, Segal HC, Sheikh S, Kallis P, Yacoub M. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg 1998 65 : 712 8.
67. Slaughter TF, LeBleu TH, Douglas JM Jr, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994 80 : 520 6.
68. Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander JC, Caprini JA. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988 59 : 62 7.
69. Yoshihara H, Yamamoto T, Mihara H. Changes in coagulation and fibrinolysis occurring in dogs during hypothermia. Thromb Res 1985 37 : 503 12.
70. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993 106 : 828 33.
71. Stibbe J, Kluft C, Brommer EJ, Gomes M, de Jong DS, Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984 14 : 375 82.
72. Lu H, Soria C, Cramer EM, Soria J, Maclouf J, Perrot JY, Li H, Commin PL, Schumann F, Regnier O, Lijnen RH, Caen JP. Temperature dependence of plasmin-induced activation or inhibition of human platelets. Blood 1991 77 : 996 1005.
73. Cramer EM, Lu H, Caen JP, Soria C, Berndt MC, Tenza D. Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood 1991 77 : 694 9.
74. Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985 65 : 32 40.
75. Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Joiner-Maier D, Santoro SA, Spitznagel E, Weitz JI, Goodnough LT. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996 76 : 902 8.
76. Hardy JF, Perrault J, Tremblay N, Robitaille D, Blain R, Carrier M. The stratification of cardiac surgical procedures according to use of blood products: a retrospective analysis of 1480 cases. Can J Anaesth 1991 38 : 511 7.
77. Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Cox JL, Barnes P, Lappas DG. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994 107 : 271 9.
78. Khuri SF, Wolfe JA, Josa M, Axford TC, Szymanski I, Assousa S, Ragno G, Patel M, Silverman A, Park M, Valeri R. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992 104 : 94 107.
79. Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK, Royston BD, Bridges CR, Higgins RS, Despotis G, Brown JR for the Society of Thoracic Surgeons Blood Conservation Guideline Task Force Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, Hill SE, Body S Society of Cardiovascular Anesthesiologist Special Task Force on Blood Transfusion. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline series. Ann Thorac Surg 2007 83 (5 Suppl S27 86.
80. Mammen EF, Koets MH, Washington BC, Wolk LW, Brown JM, Burdick M, Selik NR, Wilson RF. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985 11 : 281 92.
81. Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost 1978 5 : 1 26.
82. Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med 1986 314 : 1446 8.
83. Kalter RD, Saul CM, Wetstein L, Soriano C, Reiss RF. Cardiopulmonary bypass. Associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979 77 : 427 35.
84. Clark RE, Beauchamp RA, Magrath RA, Brooks JD, Ferguson TB, Weldon CS. Comparison of bubble and membrane oxygenators in short and long perfusions. J Thorac Cardiovasc Surg 1979 78 : 655 66.
85. Journois D, Mauriat P, Pouard P, Marchot P, Amiral J, Safran D. Assessment of coagulation factor activation during cardiopulmonary bypass with a new monoclonal antibody. J Cardiothorac Vasc Anesth 1994 8 : 157 61.
86. Gelb AB, Roth RI, Levin J, London MJ, Noall RA, Hauck WW, Cloutier M, Verrier E, Mangano DT. Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding. Am J Clin Pathol 1996 106 : 87 99.
87. Chan AK, Leaker M, Burrows FA, Williams WG, Gruenwald CE, Whyte L, Adams M, Brooker LA, Adams H, Mitchell L, Andrew M. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost 1997 77 : 270 7.
88. Muller N, Popov-Cenic S, Buttner W, Kladetzky RG, Egil H. Studies of fibrinolytic and coagulation factors during open heart surgery. II. Postoperative bleeding tendency and changes in the coagulation system. Thromb Res 1975 7 : 589 8.
89. Brooks DH, Bahnson HT. An outbreak of hemorrhage following cardiopulmonary bypass. Epidemiologic studies. J Thorac Cardiovasc Surg 1972 63 : 449 52.
90. Ellison N, Jobes DR. Effective hemostasis in the cardiac surgical patient: current status. In : Ellison N, Jobes DR, editors. Effective hemostasis in cardiac surgery. Philadelphia (PA) : W.B. Saunders 1988. p. 200.
91. Teoh KH, Young E, Bradley CA, Hirsh J. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass. Circulation 1993 88 : 420 5.
92. Meng ZH, Wolberg AS, Monroe DM III, Huffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003 55 : 886 91.
93. Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 1989 3 : 181 8.
94. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990 76 : 1680 97.
95. Czer LS. Mediastinal bleeding after cardiac surgery: etiologies, diagnostic considerations, and blood conservation methods. [Review]. J Cardiothorac Anesth 1989 3 : 760 75.
96. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991 324 : 27 39.
97. Ferraris VA, Ferraris SP, Moliterno DJ, Camp P, Walenga JM, Messmore HL, Jeske WP, Edwards FH, Royston D, Shahian DM, Peterson E, Bridges CR, Despotis G. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). Ann Thorac Surg 2005 79 : 1454 61.
98. Dietrich W, Spannagl M, Schramm W, Vogt W, Barankay A, Richter JA. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991 102 : 505 14.
99. Morris CD, Vega JD, Levy JH, Buist NN, Smith AL, Despotis GJ, Kanter KR. Warfarin therapy does not increase bleeding in patients undergoing heart transplantation. Ann Thorac Surg 2001 72 : 714 8.
100. McDonald SB, Kattapurum BM, Saleem R, Joist HJ, Avidan M, Despotis GJ. Monitoring hirudin anticoagulation in two patients undergoing cardiac surgery with a plasma-modified act method. Anesthesiology 2002 97 : 509 12.
101. Oh JJ, Akers WS, Lewis D, Ramaiah C, Flynn JD. Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy 2006 26 : 569 77.
102. Hein OV, von Heymann C, Morgera S, Konertz W, Ziemer S, Spies C. Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure. Artif Organs 2005 29 : 507 10.
103. Walsham J, Fraser JF, Mullany D, Ziegenfus M, Chinthamuneedi M, Dunning J, Tesar P. The use of recombinant activated factor VII for refractory bleeding post complex cardiothoracic surgery. Anaesth Intensive Care 2006 34 : 13 20.
104. Stratmann G, deSilva AM, Tseng EE, Hambleton J, Balea M, Romo AJ, Mann MJ, Achorn NL, Moskalik WF, Hoopes CW. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 2004 98 : 1635 9.
105. Doherty DC, Ortel TL, de Bruijn N, Greenberg CS, van Trigt P. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990 73 : 562 5.
106. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993 70 : 554 61.
107. Ganjoo AK, Harloff MG, Johnson WD. Cardiopulmonary bypass for heparin-induced thrombocytopenia: management with a heparin-bonded circuit and enoxaparin. J Thorac Cardiovasc Surg 1996 112 : 1390 2.
108. Robitaille D, Leclerc JR, Laberge R, Sahab P, Atkinson S, Cartier R. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg 1992 103 : 597 9.
109. Alvarez JM. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab. J Thorac Cardiovasc Surg 1998 115 : 472 3.
110. Gammie JS, Zenati M, Kormos RL, Hattler BG, Wei LM, Pellegrini RV, Griffith BP, Dyke CM. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998 65 : 465 9.
111. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. Am J Cardiol 1994 74 : 1166 70.
112. Raymond RE, Lincoff AM, Booth JE, Anderson KM, Miller DP, Tcheng JE, Simoons ML, Callif RM, Topol EJ. Coronary bypass surgery within 12 hours of administration of abciximab remains safe despite an increased risk of perioperative bleeding. Eur Heart J 1998 19 : 238.
113. Booth JA, Patel VB, Balog C. Is bleeding risk increased in patients undergoing urgent coronary artery bypass surgery following abciximab? Circulation 1998 98 : 845.
114. Suzuki Y, Miyamoto S, Niewiarowski S, Edmunds LH. Integrelin prevents prolonged bleeding times after cardiopulmonary bypass. Ann Thorac Surg 1998 66 : 373 81.
115. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001 29 : 2271 5.
116. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002 40 : 231 7.
117. Ray JG, Deniz S, Olivieri A, Pollex E, Vermeulen MJ, Alexander KS, Cain DJ, Cybulsky I, Hamielec CM. Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel. BMC Cardiovasc Disord 2003 3 : 1 6.
118. Genoni M, Tavakoli R, Hofer C, Bertel O, Turina M. Clopidogrel before urgent coronary artery bypass graft. J Thorac Cardiovasc Surg 2003 126 : 288 9.
119. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004 78 : 1536 41.
120. Karabulut H, Toraman F, Evrenkaya S, Goksel O, Tarcan S, Alhan C. Clopidogrel does not increase bleeding and allogenic blood transfusion in coronary artery surgery. Eur J Cardiothorac Surg 2004 25 : 419 23.
121. Englberger L, Faeh B, Berdat PA, Eberli F, Meier B, Carrel T. Impact of clopidogrel in coronary artery bypass grafting. Eur J Cardiothorac Surg 2004 26 : 96 101.
122. Chen L, Bracey AW, Radovancevic R, Cooper JR, Collard CD, Vaughn WK, Nussmeier NA. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004 128 : 425 31.
123. Kapetanakis EI, Medlam DA, Boyce SW, Haile E, Hill PC, Dullum MK, Bafi AS, Petro KR, Corso PJ. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur Heart J 2005 26 : 576 83.
124. Gansera B, Schmidtler F, Spiliopoulos K, Angelis I, Neumaier-Pauser P, Kemkes BM. Urgent or emergent coronary revascularization using bilateral internal thoracic artery after previous clopidogrel antiplatelet therapy. Thorac Cardiovasc Surg 2003 51 : 185 9.
125. von Heymann C, Redlich U, Moritz M, Sander M, Vargas HO, Grubitzsch H, Konertz WF, Spies C. Aspirin and clopidogrel taken until 2 days prior to coronary artery bypass graft surgery is associated with increased postoperative drainage loss. Thorac Cardiovasc Surg 2005 53 : 341 5.
126. Ascione R, Ghosh A, Rogers CA, Cohen A, Monk C, Angelini GD. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg 2005 79 : 1210 6.
127. NIH. Consensus conference. Fresh-frozen plasma. Indications and risks. JAMA 1985 253 : 551 3.
128. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996 84 : 732 47.
129. NIH. Consensus conference. Platelet transfusion therapy. JAMA 1987 257 : 1777 80.
130. Gravlee GP, Rogers AT, Dudas LM, Taylor R, Roy RC, Case LD, Triscott M, Brown CW, Mark LJ, Cordell AR. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992 76 : 393 401.
131. Jobes DR, Schaffer GW, Aitken GL. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995 110 : 36 45.
132. Ammar T, Fisher CF. The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology 1997 86 : 1382 6.
133. Barstad RM, Stephens RW, Hamers MJ, Sakariassen KS. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity. Thromb Haemost 2000 83 : 334 7.
134. Shastri KA, Logue GL, Stern MP, Raza S, Logue GL, O'Connor BM, Bovill JJ, Hoover EL. Neutrophil lactoferrin release during open heart surgery is unrelated to complement activation. ASAIO J 1994 40 : 56 61.
135. Moorman RM, Zapol WM, Lowenstein E. Neutralization of heparin anticoagulation. In : Gravlee GP, Davis RF, Utley JR, editors. Cardiopulmonary bypass: principles and practice. 1st ed. Baltimore (MD) : Williams & Wilkins 1993. p. 381 2.
136. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000 31 : 591 5.
137. Mochizuki T, Olson PJ, Ramsay JG, Szlam F, Levy JH. Does protamine reversal of heparin affect platelet function? Anesth Analg 1998 87 : 781 5.
138. Hayward CP. Inherited platelet disorders. Curr Opin Hematol 2003 10 : 362 8.
139. Despotis GJ, Levine V, Saleem R, Spitznagel E, Joist JH. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet 1999 354 : 106 10.
140. Beck KH, Bleckmann U, Mohr P, Kretschmer V. DDAVP's shortening of the bleeding time seems due to plasma von Willebrand factor. Semin Thromb Hemost 1995 21 : 40 3.
141. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975 30 : 81 93.
142. Hashemi S, Palmer DS, Aye MT, Ganz PR. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J Cell Physiol 1993 154 : 496 505.
143. Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, Robertson L, Donovan A, Gaffney T, Bertelé V, Troll J. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986 314 : 1402 6.
144. Dilthey G, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth 1993 7 : 425 30.
145. Salzman EW, Weinstein MJ, Reilly D, Ware JA. Adventures in hemostasis: desmopressin in cardiac surgery [review]. Arch Surg 1993 128 : 212 7.
146. Sheridan DP, Card RT, Pinilla JC, Harding SM, Thomson DJ, Gauthier L, Drotar D. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994 37 : 33 6.
147. Gratz I, Koehler J, Olsen D, Afshar M, DeCastro N, Spagna PM, Ablaza SG, Larijani GE. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 1992 104 : 1417 22.
148. Fremes SE, Wong BI, Lee E, Mai R, Christakis GT, McLean RF, Goldman BS, Naylor CD. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994 58 : 1580 8.
149. Czer LS, Bateman TM, Gray RJ, Raymond MR, Stewart ME, Lee S, Goldfinger D, Chaux A, Matloff JM. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. J Am Coll Cardiol 1987 9 : 1139 47.
150. Hackmann T, Gascoyne RD, Naiman SC, Growe GH, Burchill LD, Jamieson WR, Sheps SB, Schechter MT, Townsend GE. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 1989 321 : 1437 43.
151. Lazenby WD, Russo I, Zadeh BJ, Zelano J, Ko W, Lynch CC, Isom OW, Krieger KH. Treatment with desmopressin acetate in routine coronary artery bypass surgery to improve postoperative hemostasis. Circulation 1990 82 : 413 9.
152. Ansell J, Klassen V, Lew R, Ball S, Weinstein M, Vander Salm T, Okike N, Gratz L, Leslie J, Roberts A, Fleming N, Salzman P. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study. J Thorac Cardiovasc Surg 1992 104 : 117 23.
153. Casas JI, Zuazu-Jausoro I, Mateo J, Oliver A, Litvan H, Muniz-Diaz E, Aris A, Caralps JM, Fontcuberta J. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study. J Thorac Cardiovasc Surg 1995 110 : 1107 17.
154. Temeck BK, Bachenheimer LC, Katz NM, Coughlin SS, Wallace RB. Desmopressin acetate in cardiac surgery: a double-blind, randomized study. South Med J 1994 87 : 611 5.
155. de Prost D, Barbier-Boehm G, Hazebroucq J, Ibrahim H, Bielsky MC, Hvass U, Lacombe C, Francais JL, Desmonts JM. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass. Thromb Haemost 1992 68 : 106 10.
156. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992 77 : 38 46.
157. Lemmer JH Jr, Stanford W, Bonney SL, Chomka EV, Karp RB, Laub GW, Rumberger JA, Schaff HV. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994 107 : 543 53.
158. Lemmer JH, Dilling EW, Morton JR, Rich JB, Robicsek F, Bricker DL, Hantler CB, Whitten CW, Noon GP, Maddi R. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996 62 : 1659 67.
159. Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995 92 : 2236 44.
160. Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, Uretzky G, Pettersson G, Thiis JJ, Hantler CB, Chaitman B, Nadel A. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998 116 : 716 30.
161. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briet E, Buller HR. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999 354 : 1940 7.
162. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006 46 : 327 38.
163. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006 354 : 353 65.
164. Aprotinin injection (marketed as Trasylol) information [Internet]. FDA 2007 Nov 5. Available from: http://www.fda.gov/cder/drug/infopage/aprotinin/ default.htm
165. Alvarez JM, Jackson LR, Chatwin C, Smolich JJ. Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 2001 122 : 457 63.
166. Cicek S, Demirkilic U, Ozal E, Kuralay E, Bingol H, Tatar H, Ozturk OY. Postoperative use of aprotinin in cardiac operations: an alternative to its prophylactic use. J Thorac Cardiovasc Surg 1996 112 : 1462 7.
167. Ray MJ, Hales MM, Brown L, O'Brien MF, Stafford GE. Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit. Ann Thorac Surg 2001 72 : 521 6.
168. Tatar H, Cicek S, Demirkilic U, Ozal E, Suer H, Ozturk O, Isiklar H. Topical use of aprotinin in open heart operations. Ann Thorac Surg 1993 55 : 659 61.
169. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003 43 : 668 76.
170. Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006 32 (Suppl 1 98 110.
171. Lundblad RL, Bradshaw RA, Gabriel D, Ortel TL, Lawson J, Mann KG. A review of the therapeutic uses of thrombin. Thromb Haemost 2004 91 : 851 60.
172. Goodnough LT, Johnston MF, Toy PT. The variability of transfusion practice in coronary artery bypass surgery. Transfusion Medicine Academic Award Group. JAMA 1991 265 : 86 90.
173. Goodnough LT, Soegiarso RW, Birkmeyer JD, Welch HG. Economic impact of inappropriate blood transfusions in coronary artery bypass graft surgery. Am J Med 1993 94 : 509 14.
174. Surgenor DM, Wallace EL, Churchill WH, Hao SH, Chapman RH, Collins JJ Jr. Red cell transfusions in coronary artery bypass surgery (DRGs 106 and 107) [published erratum appears in Transfusion 1992;32:876]. Transfusion 1992 32 : 458 64.
175. Stover EP, Siegel LC, Parks R, Levin J, Body SC, Maddi R, D'Ambra MN, Mangano DT, Spiess BD. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology 1998 88 : 327 33.
176. Simon TL, Akl BF, Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 1984 37 : 359 64.
177. Milam JD, Austin SF, Martin RF, Keats AS, Cooley DA. Alteration of coagulation and selected clinical chemistry parameters in patients undergoing open heart surgery without transfusions. Am J Clin Pathol 1981 76 : 155 62.
178. Counts RB. Transfusion practice in cardiac surgery: causes of bleeding in open-heart surgery. Arlington (VA) : American Association of Blood Banks 1991. p. 1 10.
179. Despotis GJ, Grishaber JE, Goodnough LT. The effect of an intraoperative treatment algorithm on physicians' transfusion practice in cardiac surgery. Transfusion 1994 34 : 290 6.
180. Paone G, Spencer T, Silverman NA. Blood conservation in coronary artery surgery. Surgery 1994 116 : 672 7.
181. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995 9 : 168 73.
182. Nuttall GA, Oliver WC, Santrach PJ, Bryant SC, Dearani JA, Schaff HV, Ereth MH. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001 94 : 773 81.
183. Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth 2001 86 : 575 8.
184. Avidan MS, Alcock EL, Da Fonseca J, Ponte J, Desai JB, Despotis GJ, Hunt BJ. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004 92 : 178 86.
185. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999 88 : 312 9.
186. Capraro L, Kuitunen A, Salmenpera M, Kekomäki R. On-site coagulation monitoring does not affect hemostatic outcome after cardiac surgery. Acta Anaesthesiol Scand 2001 45 : 200 6.
187. Despotis GJ, Levine V, Filos KS, Santoro SA, Joist JH, Spitznagel E, Goodnough LT. Evaluation of a new, point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996 85 : 1311 23.
188. Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Barnes P, Cox JL, Lappas DG. On-site prothrombin time, activated partial thromboplastin time, and platelet count. A comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery. Anesthesiology 1994 80 : 338 51.
189. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002 42 : 114 24.
190. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegaard J, Holm J, Kutti J, Mellqvist U-H, Johansson JE, Glazer S, Hedner U. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996 26 : 159 64.
191. Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999 94 : 3951 3.
192. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006 295 : 293 8.
193. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004 44 : 1325 31.
194. Jeroukhimov I, Jewelewicz D, Zaias J, Hensley G, MacLeod J, Cohn SM, Scalea TM. Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma 2002 53 : 1053 7.
195. Schreiber MA, Holcomb JB, Hedner U, Brundage SI, Macaitis JM, Hoots K. The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma 2002 53 : 252 7.
196. Arkin S, Blei F, Fetten J, Foulke R, Gilchrist GS, Heisel MA, Key N, Kisker CT, Kitchen C, Shafer FE, Shah PC, Strickland D. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000 11 : 255 9.
197. White B, McHale J, Ravi N, Reynolds J, Stephen R, Moriarty J, Smith OP. Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999 107 : 677 8.
198. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingersiev J, Lynn M. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001 51 : 431 8.
199. Weiskopf RB. Intraoperative use of recombinant activated coagulation factor vII. Anesthesiology 2002 96 : 1287 9.
200. Chuansumrit A, Chantarojanasiri T, Isarangkura P, Teeraratkul S, Hongeng S, Hathirat P. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000 11 : 101 5.
201. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005 352 : 777 85.
202. Egan JR, Lammi A, Schell DN, Gillis J, Nunn GR. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med 2004 30 : 682 5.
203. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb 2002 32 : 41 6.
204. Sheth S, Dimichele D, Lee M, Lamour J, Quaegebeur J, Hsu D, Addonizio L, Piomelli S. Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa. Haemophilia 2001 7 : 227 32.
205. Leibovitch L, Kenet G, Mazor K, Matok I, Vardi Barzilay Z, Paret G. Recombinant activated factor VII for life-threatening pulmonary hemorrhage after pediatric cardiac surgery. Pediatr Crit Care Med 2003 4 : 444 6.
206. Tokunaga C, Hiramatsu Y, Horigome H, Takahashi-Igari M, Noma M, Sakakibara Y. Palliative open heart surgery in an infant with factor VII deficiency. Ann Thorac Surg 2003 76 : 2093 4.
207. Pychynska-Pokorska M, Moll JJ, Krajewski W, Jarosik P. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 2004 5 : 246 50.
208. Yilmaz BT, Alioglu B, Ozyurek E, Akay HT, Mercan S, Ozbek N. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol 2005 26 : 843 5.
209. Lucey MA, Myburgh JA. Recombinant activated factor VII for exsanguinating haemorrhage post bilateral lung transplantation for extra-corporeal lung support-dependent respiratory failure. Anaesth Intensive Care 2003 31 : 465 9.
210. Verrijckt A, Proulx F, Morneau S, Vobecky S, Rivard GE. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 2004 127 : 1812 3.
211. Dominguez TE, Mitchell M, Friess SH, Huh JW, Manno CS, Ravishankaer C, Gaynor JW, Tabbutt S. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2005 6 : 348 51.
212. Wittenstein B, Ng C, Ravn H, Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med 2005 473 6.
213. Razon Y, Erez E, Vidne B, Birk E, Katz J, Dagan O. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth 2005, 235 40.
214. Malherbe S, Tsui BC, Stobart K, Koller J. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004 100 : 443 5.
215. Tanaka KA, Waly AA, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003 98 : 1513 5.
216. Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001 93 : 287 9.
217. Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002 124 : 852 4.
218. Zietkiewicz M, Garlicki M, Domagala J, Wierzbicki K, Drwila R, Pfitzner R, Dziatkowiak A. Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg 2002 123 : 384 5.
219. Kastrup M, von Heymann C, Hotz H, Konertz WF, Ziemer S, Kox WJ, Spies C. Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg 2002 74 : 910 2.
220. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003 4 : 49 51.
221. Stratmann G, Russell IA, Merrick SH. Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair. Ann Thorac Surg 2003 76 : 2094 7.
222. Diprose P, Gill R, Herbertson M. Is recombinant factor VIIa a universal hemostatic agent? In : Vincent JL, editor. Berlin : Springer-Verlag 2006. p. 136 46.
223. Naik VN, Mazer CD, Latter DA, Teitel JM, Hare GM. Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth 2003 50 : 599 602.
224. O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003 43 : 1711 6.
225. Aggarwal A, Malkovska V, Catlett JP, Alcorn K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. Thromb J 2004 2 : 9.
226. Kogan A, Berman M, Stein M, Vidne BA, Raanani E. Recombinant factor VIIa use in cardiac surgery - expanding the arsenal therapy for intractable bleeding? J Cardiovasc Surg (Torino) 2004 45 : 569 71.
227. Vanek T, Straka Z, Hrabak J, Jares M, Brucek PJ, Votava J. Use of recombinant activated factor VII in cardiac surgery for an effective treatment of severe intractable bleeding. Jpn Heart J 2004 45 : 855 60.
228. Flynn JD, Pajoumand M, Camp PC Jr, Jahania MS, Ramaiah C, Akers WS. Recombinant factor VIIa for refractory bleeding following orthotopic heart transplantation. Ann Pharmacother 2004 38 : 1639 42.
229. McIlroy DR, Silvers AJ. Recombinant factor VIIa for life-threatening bleeding in high-risk cardiac surgery despite full-dose aprotinin. Anesth Analg 2004 99 : 27 30.
230. Halkos ME, Levy JH, Chen E, Reddy VS, Lattouf OM, Guyton RA, Song HK. Early experience with activated recombinant factor VII for intractable hemorrhage following cardiovascular surgery. Ann Thorac Surg 2005 67 : 1 11.
231. Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg 2005 28 : 254 8.
232. von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Sander M, Grosse J, Ziemer S, Koscielny J, Konertz WF, Wernecke KD, Spies C. Recombinant activated factor VII for refractory bleeding after cardiac surgery - a retrospective analysis of safety and efficacy. Crit Care Med 2005 33 : 2241 6.
233. Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg 2005 80 : 66 71.
234. von Heymann C, Schoenfeld H, Sander M, Ziemer S, Grubitzsch H, Spies C. Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates? Heart Surg Forum 2005 8 : 39 41.
235. Gowers CJ, Parr MJ. Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesth Intensive Care 2005 33 : 196 200.
236. Karkouti K, Beattie WS, Wijeysundera DN, Yau TM, McCluskey SA, Ghannam M, Sutton D, van Rensburg A, Karski J. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005 45 : 26 34.
237. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005 95 : 596 602.
238. Bishop CV, Renwick WE, Hogan C, Haeusler M, Tuckfield A, Tatoulis J. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 2006 81 : 875 9.
239. Romagnoli S, Bevilacqua S, Gelsomino S, Pradella S, Ghilli L, Rostagno C, Gensini GF, Sorbara C. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 2006 102 : 1320 6.
240. DiDomenico RJ, Massad MG, Kpodonu J, Navarro RA, Geha A. Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass. Chest 2005 127 : 1828 35.
241. Velik-Salchner C, Sergi C, Fries D, Moser P, Streif W, Kolbitsch C. Use of recombinant factor VIIa (Novoseven) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporal membrane oxygenation. Anesth Analg 2005 101 : 924.
242. Clark AD, Gordon WC, Walker ID, Tait RC. "Last-ditch" use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004 86 : 120 4.
243. Karkouti K, Yau TM, Riazi S, Dattilo KM, Wasowicz M, Meineri M, McCluskey SA, Wijeysundera DN, van Rensburg A, Beattie WS. Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anaesth 2006 53 : 802 9.
244. Potapov EV, Pasic M, Bauer M, Hetzer R. Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device. Ann Thorac Surg 2002 74 : 2182 3.
245. Eikelboom JW, Bird R, Blythe D, Coyle L, Gan E, Harvey M, Isbister J, Leahy M, McIlroy D, Rahimpanah F, Ramanthan S, Strasser S, Ward C, Watts A, Towler S, Yi Q. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 2003 14 : 713 7.
246. Tobias JD, Simsic JM, Weinstein S, Schechter W, Kartha V, Michler R. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J Intensive Care Med 2004 19 : 270 3.
247. Mulry CC, Le Veen RF, Sobel M, Lampe PJ, Burke DR. Assessment of heparin anticoagulation during peripheral angioplasty. J Vasc Interv Radiol 1991 2 : 133 9.
248. de Jonge E, Friederich PW, Vlasuk GP, Rote WE, Vroom MB, Levi M, Van Der PT. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diagn Lab Immunol 2003 10 : 495 7.
249. Zilla P, Fasol R, Groscurth P, Klepetko W, Reichenspurner H, Wolner E. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg 1989 97 : 379 88.
250. Pickard JD, Kirkpatrick PJ, Melsen T, Andreasen RB, Gelling L, Fryer T, Matthews J, Minhas P, Hutchinson PJ. Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis 2000 11 : 117 20.
251. Laffan M, O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy D, Smith OP. Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagul Fibrinolysis 2003 14 : 35 8.
252. Heuer L, Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinolysis 2005 16 : 287 90.
253. Lovejoy AE, Reynolds TC, Visich JE, Butine MD, Young G, Belvedere MA, Blain RC, Pederson SM, Ishak LM, Nugent DJ. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006 108 : 57 62.
254. Reynolds TC, Butine MD, Visich JE, Ishak LM, Belvedere MA, Nugent DJ. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers. J Thromb Haemost 2005 3 : 922 8.
255. Godje O, Haushofer M, Lamm P, Reichart B. The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg 1998 46 : 263 7.
256. Godje O, Gallmeier U, Schelian M, Grunewald M, Mair H. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 2006 54 : 26 33.
257. Shainoff JR, Estafanous FG, Yared JP, DiBello PM, Kottke-Marchant K, Loop FD. Low factor XIIIA levels are associated with increased blood loss after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994 108 : 437 45.
258. Blome M, Isgro F, Kiessling AH, Skuras J, Haubelt H, Hellstern P, Saggau W. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005 93 : 1101 7.
259. Chandler WL, Patel MA, Gravelle L, Soltow L, Lewis K, Bishop PD, Spiess BD. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001 12 : 101 8.
260. Koneti RA. Chapter 64: hereditary disorders of platelet secretion and signal transfuction. In : Colman RW, Clowes AW, George JN, Goldhaber S, Marder VJ, editors. Hemostasis and thrombosis. 5th ed. New York : Lippincott Williams and Wilkens 2006. p. 961 9.
261. Koscielny J, Ziemer S, Radtke H, Pruss A, Schmutzler M, Sinha P, Salama A, Kiesewetter H, Latza R. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004 10 : 195 204.
262. Lindvall G, Sartipy U, van der Linden J. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting. Ann Thorac Surg 2005 80 : 922 7.
263. Koscielny J, von Tempelhoff GF, Ziemer S, Radtke H, Schmutzler M, Sinha P, Salama A, Kiesewetter H, Latza RA. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004 10 : 155 66.
264. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med 2005 56 : 173 91. 173 91.
265. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003 101 : 2089 93.
266. Ferraris VA, Ferraris SP, Singh A, Fuhr W, Koppel D, McKenna D, Rodriguez E, Reich H. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg 1998 65 : 352 8.
267. Blauhut B, Harringer W, Bettelheim P, Doran J, Spath P, Lungsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994 108 : 1083 91.
268. Chandler WL, Fitch JC, Wall MH, Verrier ED, Cochran RP, Soltow LO, Spiess BD. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 1995 74 : 1293 7.
269. Milam JD. Blood transfusion in heart surgery. Clin Lab Med 1982 2 : 65 85.
270. Edmunds LH Jr, Ellison N, Colman RW, Niewiarowski S, Rao AK, Addonizio VP Jr, Stephenson LW, Edie RN. Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1982 83 : 805 12.
271. Boldt J, Kling D, Zickmann B, Jacobi M, Dapper F, Hempelmann G. Acute plasmapheresis during cardiac surgery: volume replacement by crystalloids versus colloids. J Cardiothorac Anesth 1990 4 : 564 70.
272. Gluszko P, Rucinski B, Musial J, Wenger RK, Schmaier AH, Colman RW, Edmunds LH Jr, Niewiarowski S. Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. Am J Physiol 1987 252 : 615 21.
273. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986 78 : 340 8.
274. Rinder CS, Mathew JP, Rinder HM, Bonan J, Ault KA, Smith BR. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology 1991 75 : 563 70.
275. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991 75 : 388 93.
276. Beurling-Harbury C, Galvan CA. Acquired decrease in platelet secretory ADP associated with increased postoperative bleeding in post-cardiopulmonary bypass patients and in patients with severe valvular heart disease. Blood 1978 52 : 13 23.
277. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990 99 : 788 97.
278. Harker LA, Malpass TW, Branson HE, Hessel EA 2nd, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980 56 : 824 34.
279. Addonizio VP Jr, Fisher CA, Kappa JR, Ellison N. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). Surgery 1987 102 : 796 807.
280. Okita YO, Takamoto S, Ando M, Morota T, Yamaki F, Matsukawa R, Kawashima Y. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization. Circulation 1997 96 : 376 81.
281. Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 1991 38 : 113 9.
282. Wachtfogel YT, Kucich U, Greenplate J, Gluszko P, Abrams W, Weinbaum G, Wenger RK, Rucinski B, Niewiarowski S, Edmunds LH, Colman RW. Human neutrophil degranulation during extracorporeal circulation. Blood 1987 69 : 324 30.
283. Teoh KH, Christakis GT, Weisel RD, Madonik MM, Ivanov J, Wong PY, Mee AV, Levitt D, Benak A, Reilly P. Blood conservation with membrane oxygenators and dipyridamole. Ann Thorac Surg 1987 44 : 40 7.
284. Musial J, Niewiarowski S, Rucinski B, Stewart GJ, Cook JJ, Williams JA, Edmunds LH Jr. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms. Circulation 1990 82 : 261 73.
285. Shore-Lesserson L, Fisher C, Ammar T, Sarier K, DePerio M. Comparison of hemoSTATUS with flow cytometric analysis of platelet function during cardiac surgical procedures. Anesth Analg 1997 84 : 108.
286. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK. Comparison of platelet membrane markers for the detection of platelet activation in vitro and during platelet storage and cardiopulmonary bypass surgery. J Lab Clin Med 1993 121 : 579 87.
287. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992 79 : 1201 5.
288. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990 75 : 128 38.
289. Valeri CR, Feingold H, Cassidy G, Ragno G, Khuri S, Altschule MD. Hypothermia-induced reversible platelet dysfunction. Ann Surg 1987 205 : 175 81.
290. Faraday N, Rosenfeld BA. In vitro hypothermia enhances platelet GPIIb-IIIa activation and P-selectin expression. Anesthesiology 1998 88 : 1579 85.
291. Valeri CR, Khabbaz K, Khuri SF, Marquardt C, Ragno G, Feinhold H, Gray AD, Axford T. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. J Thorac Cardiovasc Surg 1992 104 : 108 16.
292. Michelson AD, MacGregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 1994 71 : 633 40.
293. Carr ME Jr, Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb Res 1994 75 : 617 30.
294. John LC, Rees GM, Kovacs IB. Different anticoagulants and platelet reactivity in cardiac surgical patients. Ann Thorac Surg 1993 56 : 899 902.
295. Fernandez F, N'guyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986 43 : 491 5.
296. John LC, Rees GM, Kovacs IB. Reduction of heparin binding to and inhibition of platelets by aprotinin. Ann Thorac Surg 1993 55 : 1175 9.
297. John LC, Rees GM, Kovacs IB. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 1993 105 : 816 22.
298. Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991 87 : 1787 93.
299. Suzuki K, Nishioka J, Hashimoto S. Inhibition of factor VIII-associated platelet aggregation by heparin and dextran sulfate, and its mechanism. Biochim Biophys Acta 1979 585 : 416 26.
300. Khuri SF, Valeri CR, Loscalzo J, Weinstein MJ, Birjiniuk V, Healey NA, MacGregor H, Doursounian M, Zolkewitz BS. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995 60 : 1008 14.
301. Boldt J, Schindler E, Osmer C, Wittstock M, Stertmann WA, Hempelmann G. Influence of different anticoagulation regimens on platelet function during cardiac surgery. Br J Anaesth 1994 73 : 639 44.
302. von Heymann C, Hotz H, Konertz W, Kox WJ, Spies C. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2002 16 : 615 6.